Mechanisms of Resistance to Endocrine Therapy in Breast Cancer: Focus on Signaling Pathways, miRNAs and Genetically Based Resistance
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Mechanisms of Resistance to Endocrine Therapy in Breast Cancer: Focus on Signaling Pathways, miRNAs and Genetically Based Resistance
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 14, Issue 1, Pages 108-145
Publisher
MDPI AG
Online
2012-12-21
DOI
10.3390/ijms14010108
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Simultaneous Inhibition of Estrogen Receptor and the HER2 Pathway in Breast Cancer: Effects of HER2 Abundance
- (2014) Anna Emde et al. Translational Oncology
- Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer
- (2012) Line L Haugan Moi et al. BMC CANCER
- SULT1A1 rs9282861 polymorphism-a potential modifier of efficacy of the systemic adjuvant therapy in breast cancer?
- (2012) Maria Tengström et al. BMC CANCER
- Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies
- (2012) Albert C. Chen et al. BREAST CANCER RESEARCH AND TREATMENT
- Mechanisms of estrogen-independent breast cancer growth driven by low estrogen concentrations are unique versus complete estrogen deprivation
- (2012) Matthew J. Sikora et al. BREAST CANCER RESEARCH AND TREATMENT
- Overcoming acquired resistance to letrozole by targeting the PI3K/AKT/mTOR pathway in breast cancer cell clones
- (2012) Andrea Cavazzoni et al. CANCER LETTERS
- Acquired Resistance to Tamoxifen Is Associated with Loss of the Type I Insulin-like Growth Factor Receptor: Implications for Breast Cancer Treatment
- (2012) D. H. Fagan et al. CANCER RESEARCH
- Cross-talk between HER2 and MED1 Regulates Tamoxifen Resistance of Human Breast Cancer Cells
- (2012) J. Cui et al. CANCER RESEARCH
- AIB1:ER Transcriptional Activity Is Selectively Enhanced in Aromatase Inhibitor-Resistant Breast Cancer Cells
- (2012) J. O'Hara et al. CLINICAL CANCER RESEARCH
- MicroRNAs as therapeutic targets and their potential applications in cancer therapy
- (2012) William CS Cho EXPERT OPINION ON THERAPEUTIC TARGETS
- Germline pharmacogenomics in oncology: Decoding the patient for targeting therapy
- (2012) Peter H. O'Donnell et al. Molecular Oncology
- Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?
- (2012) Karin Beelen et al. Nature Reviews Clinical Oncology
- Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells
- (2012) S Cutrupi et al. ONCOGENE
- Toward Individualized Breast Cancer Therapy: Translating Biological Concepts to the Bedside
- (2012) G. N. Hortobagyi ONCOLOGIST
- Global MicroRNA Expression Profiling of High-Risk ER+ Breast Cancers from Patients Receiving Adjuvant Tamoxifen Mono-Therapy: A DBCG Study
- (2012) Maria B. Lyng et al. PLoS One
- Position paper: The membrane estrogen receptor GPER – Clues and questions
- (2012) Matthias Barton STEROIDS
- An Overview of Letrozole in Postmenopausal Women with Hormone-Responsive Breast Cancer
- (2011) Agustí Barnadas et al. ADVANCES IN THERAPY
- Breast cancer and microRNAs: therapeutic impact
- (2011) Marilena V. Iorio et al. BREAST
- Guide to Receptors and Channels (GRAC), 5th edition
- (2011) SPH Alexander et al. BRITISH JOURNAL OF PHARMACOLOGY
- Differential expression of microRNA expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells
- (2011) Tissa T. Manavalan et al. CANCER LETTERS
- Global Characterization of the SRC-1 Transcriptome Identifies ADAM22 as an ER-Independent Mediator of Endocrine-Resistant Breast Cancer
- (2011) D. McCartan et al. CANCER RESEARCH
- Metastatic Progression with Resistance to Aromatase Inhibitors Is Driven by the Steroid Receptor Coactivator SRC-1
- (2011) J. McBryan et al. CANCER RESEARCH
- Functional Activation of the Estrogen Receptor- and Aromatase by the HDAC Inhibitor Entinostat Sensitizes ER-Negative Tumors to Letrozole
- (2011) G. J. Sabnis et al. CANCER RESEARCH
- MicroRNA-301 Mediates Proliferation and Invasion in Human Breast Cancer
- (2011) W. Shi et al. CANCER RESEARCH
- Adaptive Changes Result in Activation of Alternate Signaling Pathways and Acquisition of Resistance to Aromatase Inhibitors
- (2011) A. Brodie et al. CLINICAL CANCER RESEARCH
- The Role of Antiangiogenetic Agents in the Treatment of Breast Cancer
- (2011) M. A. Bareschino et al. CURRENT MEDICINAL CHEMISTRY
- Pharmacogenomics of Tamoxifen: Roles of Drug Metabolizing Enzymes and Transporters
- (2011) Kazuma Kiyotani et al. Drug Metabolism and Pharmacokinetics
- Scriptaid effects on breast cancer cell lines
- (2011) L. Giacinti et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer
- (2011) Todd W. Miller et al. JOURNAL OF CLINICAL ONCOLOGY
- Downregulation of miR-342 is associated with tamoxifen resistant breast tumors
- (2011) Diana M Cittelly et al. Molecular Cancer
- Tamoxifen downregulation of miR-451 increases 14-3-3ζ and promotes breast cancer cell survival and endocrine resistance
- (2011) A Bergamaschi et al. ONCOGENE
- Global MicroRNA Expression Profiling Identifies MiR-210 Associated with Tumor Proliferation, Invasion and Poor Clinical Outcome in Breast Cancer
- (2011) Françoise Rothé et al. PLoS One
- Importance of PI3-kinase pathway in response/resistance to aromatase inhibitors
- (2011) Cynthia X. Ma et al. STEROIDS
- Cancer epigenetics: a perspective on the role of DNA methylation in acquired endocrine resistance
- (2011) Michael P. Trimarchi et al. Chinese Journal of Cancer
- microRNA and Cancer
- (2010) Mengfeng Li et al. AAPS Journal
- The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells
- (2010) Selma Masri et al. BREAST CANCER RESEARCH AND TREATMENT
- EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy
- (2010) A H Evans et al. BRITISH JOURNAL OF CANCER
- Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis
- (2010) Nobuyoshi Kosaka et al. CANCER SCIENCE
- Oncogenic HER2Δ16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors
- (2010) Diana M. Cittelly et al. CARCINOGENESIS
- Effect of Low-Dose Tamoxifen on Steroid Receptor Coactivator 3/Amplified in Breast Cancer 1 in Normal and Malignant Human Breast Tissue
- (2010) L. L. Haugan Moi et al. CLINICAL CANCER RESEARCH
- Lapatinib Restores Hormone Sensitivity with Differential Effects on Estrogen Receptor Signaling in Cell Models of Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer with Acquired Endocrine Resistance
- (2010) A. F. Leary et al. CLINICAL CANCER RESEARCH
- Hormone-Biological Therapy in Breast Cancer: Preclinical Evidence,Clinical Studies and Future Directions
- (2010) G. Schiavon et al. CURRENT CANCER DRUG TARGETS
- Steroid receptor and microRNA regulation in cancer
- (2010) Michael A Tessel et al. CURRENT OPINION IN ONCOLOGY
- Minireview: Steroid Receptor Coactivator-3: A Multifarious Coregulator in Mammary Gland Metastasis
- (2010) John P. Lydon et al. ENDOCRINOLOGY
- An estrogen receptor α suppressor, microRNA-22, is downregulated in estrogen receptor α-positive human breast cancer cell lines and clinical samples
- (2010) Jianhua Xiong et al. FEBS Journal
- Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor–positive human breast cancer
- (2010) Todd W. Miller et al. JOURNAL OF CLINICAL INVESTIGATION
- Epigenetic Regulation in Estrogen Receptor Positive Breast Cancer—Role in Treatment Response
- (2010) Thushangi N. Pathiraja et al. JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA
- Estrogen receptor alpha 46 is reduced in tamoxifen resistant breast cancer cells and re-expression inhibits cell proliferation and estrogen receptor alpha 66-regulated target gene transcription
- (2010) Carolyn M. Klinge et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- MicroRNA-101-mediated Akt activation and estrogen-independent growth
- (2010) M Sachdeva et al. ONCOGENE
- MicroRNA-221/222 confers breast cancer fulvestrant resistance by regulating multiple signaling pathways
- (2010) X Rao et al. ONCOGENE
- Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer
- (2009) A. U. Buzdar ANNALS OF ONCOLOGY
- Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors
- (2009) M Hauglid Flågeng et al. BRITISH JOURNAL OF CANCER
- Loss of Phosphatase and Tensin Homologue Deleted on Chromosome 10 Engages ErbB3 and Insulin-Like Growth Factor-I Receptor Signaling to Promote Antiestrogen Resistance in Breast Cancer
- (2009) T. W. Miller et al. CANCER RESEARCH
- Trastuzumab Reverses Letrozole Resistance and Amplifies the Sensitivity of Breast Cancer Cells to Estrogen
- (2009) Gauri Sabnis et al. CANCER RESEARCH
- 14-3-3 Overexpression Defines High Risk for Breast Cancer Recurrence and Promotes Cancer Cell Survival
- (2009) C. L. Neal et al. CANCER RESEARCH
- Coassociation of Estrogen Receptor and p160 Proteins Predicts Resistance to Endocrine Treatment; SRC-1 is an Independent Predictor of Breast Cancer Recurrence
- (2009) A. M. Redmond et al. CLINICAL CANCER RESEARCH
- Role of ADAMs in Cancer Formation and Progression
- (2009) M. J. Duffy et al. CLINICAL CANCER RESEARCH
- Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer
- (2009) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
- (2009) Bella Kaufman et al. JOURNAL OF CLINICAL ONCOLOGY
- An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance
- (2009) D. Mitra et al. MOLECULAR CANCER THERAPEUTICS
- Conserved estrogen binding and signaling functions of the G protein-coupled estrogen receptor 1 (GPER) in mammals and fish
- (2009) P. Thomas et al. STEROIDS
- Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance
- (2008) Fuxiao Xin et al. BIOINFORMATICS
- Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome
- (2008) Malini Harigopal et al. BREAST CANCER RESEARCH AND TREATMENT
- Inhibition of histone deacetylase suppresses EGF signaling pathways by destabilizing EGFR mRNA in ER-negative human breast cancer cells
- (2008) Qun Zhou et al. BREAST CANCER RESEARCH AND TREATMENT
- Rational management of endocrine resistance in breast cancer
- (2008) Sara A. Hurvitz et al. CANCER
- Identification of CDK10 as an Important Determinant of Resistance to Endocrine Therapy for Breast Cancer
- (2008) Elizabeth Iorns et al. CANCER CELL
- Genome-Wide Analysis of Aromatase Inhibitor-Resistant, Tamoxifen-Resistant, and Long-Term Estrogen-Deprived Cells Reveals a Role for Estrogen Receptor
- (2008) S. Masri et al. CANCER RESEARCH
- miR-206 Expression Is Down-regulated in Estrogen Receptor -Positive Human Breast Cancer
- (2008) N. Kondo et al. CANCER RESEARCH
- The Role of Amphiregulin in Exemestane-Resistant Breast Cancer Cells: Evidence of an Autocrine Loop
- (2008) X. Wang et al. CANCER RESEARCH
- Cross-talk between Notch and the Estrogen Receptor in Breast Cancer Suggests Novel Therapeutic Approaches
- (2008) P. Rizzo et al. CANCER RESEARCH
- Broad Antitumor Activity in Breast Cancer Xenografts by Motesanib, a Highly Selective, Oral Inhibitor of Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors
- (2008) A. Coxon et al. CLINICAL CANCER RESEARCH
- MicroRNA-221/222 Negatively Regulates Estrogen Receptorα and Is Associated with Tamoxifen Resistance in Breast Cancer
- (2008) Jian-Jun Zhao et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- MicroRNA-221/222 Confers Tamoxifen Resistance in Breast Cancer by Targeting p27Kip1
- (2008) Tyler E. Miller et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- ERα negative breast cancer cells restore response to endocrine therapy by combination treatment with both HDAC inhibitor and DNMT inhibitor
- (2008) Jiang Fan et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
- (2008) LANCET ONCOLOGY
- An Autocrine VEGF/VEGFR2 and p38 Signaling Loop Confers Resistance to 4-Hydroxytamoxifen in MCF-7 Breast Cancer Cells
- (2008) R. Aesoy et al. MOLECULAR CANCER RESEARCH
- Regulation of ERBB2 by oestrogen receptor–PAX2 determines response to tamoxifen
- (2008) Antoni Hurtado et al. NATURE
- Epigenomics and breast cancer
- (2008) Pang-Kuo Lo et al. PHARMACOGENOMICS
- Four miRNAs associated with aggressiveness of lymph node-negative, estrogen receptor-positive human breast cancer
- (2008) J. A. Foekens et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Membrane association of estrogen receptor α and β influences 17β-estradiol-mediated cancer cell proliferation
- (2008) M MARINO et al. STEROIDS
- The functional implications of Akt activity and TGF-β signaling in tamoxifen-resistant breast cancer
- (2007) Young A. Yoo et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started